Subtle. Cumulative. Not a felt stimulant. Closer to astaxanthin or ALCAR in subjective profile than to modafinil or rhodiola.

• Acute (first week): Most users report nothing definitive. A minority report mild energy/clarity within 2-5 hours of a 90-180 mg dose; this could be NQO1-genotype-dependent — fast-NQO1 responders may notice acute lift, slow-NQO1 may not.
• Subacute (weeks 1-3): Mild improvement in mental endurance during long cognitive sessions. Some users report tinnitus reduction (mechanism unclear, possibly cochlear mitochondrial protection). Reduced post-training mental fog if MMA-volume is high.
• Chronic (weeks 4-12): This is where the clinical-trial signals show up — improved verbal memory + delayed recall (per the 2024 aMCI study), reduced subjective fatigue (per Friedreich's open-ended interviews), eye/vision-fatigue improvement at higher doses (per LHON real-world reports).
• Feels like: an "all-day clarity floor raised slightly" rather than a peak-shifted state. Comparable to the cumulative effect of a clean astaxanthin + ALCAR stack rather than a discrete cognitive event.
• Variability: High. NQO1 polymorphism status (~25-50% Caucasian prevalence of low-activity variant) probably explains most of the responder/non-responder split in healthy users. Hepatic CYP2D6 status modulates exposure too — CYP2D6 poor metabolizers may have higher exposure.

• Tolerance buildup: None reported clinically. LHON patients have used 900 mg/day continuously for years without dose escalation or loss of effect. Mechanism is metabolic/structural, not receptor-mediated.
• Recommended cycle: Optional but reasonable. Russian Noben labeling uses 1.5-2 month courses with breaks (2-3 courses/year). Western LHON labeling is continuous. For Dylan, an 8-12 week run with a check-the-numbers reset is reasonable; alternatively, continuous use is supported by the LHON safety record.
• Reset protocol: Not strictly necessary. If discontinuation is desired, no taper required; clinical effect washes out over 2-4 weeks (tissue redistribution).

Synergistic with

• astaxanthin (Dylan's V5 plan, 12 mg AM): Strongly synergistic and the cleanest pairing. Both are BBB-crossing lipid-membrane antioxidants but at different depths/mechanisms — astaxanthin is a membrane-spanning structural antioxidant (polyene chain quenches the bilayer interior + Nrf2 induction); idebenone is a smaller, more mobile electron-shuttle antioxidant that also activates Nrf2. Layered membrane protection + redundancy of upstream signaling. Mechanistically, idebenone protects the inner mitochondrial membrane phospholipids that astaxanthin doesn't reach as well; astaxanthin protects neuronal plasma membrane phospholipids that idebenone doesn't anchor to. Take them together at breakfast with fish oil for absorption.
• alcar (Dylan's V5 plan, 500 mg AM): Strongly synergistic and the most relevant overlap to think about. ALCAR carries fatty acids into the mitochondrial matrix for β-oxidation; idebenone makes downstream ETC use of those electrons more efficient (complex III bypass) and protects the membranes against the lipid-peroxidation byproducts. The ALCAR + idebenone pair is the canonical mitochondrial cognitive stack in older nootropic literature. Co-administer at breakfast.
• CoQ10 / ubiquinol: Mechanistically complementary in healthy adults — CoQ10 supports the inner-mitochondrial-membrane pool while idebenone provides the BBB-crossing soluble pool. Doesn't cross BBB well so doesn't compete in brain. Pair if budget allows; not strictly necessary if idebenone is on board.
• NAC (Dylan's V4, 1200 mg/day): Glutathione precursor; complementary upstream antioxidant. NAC supports the cytoplasmic glutathione pool that allows idebenone's hydroquinone form to function without being overwhelmed. Already in V4 — no change needed.
• cerebrolysin (Dylan's V5 plan, 5 mL IM × 10-20 days q3mo): Mechanistically complementary, not redundant. Cerebrolysin is a neurotrophic peptide cocktail (BDNF/NGF mimetics + low-MW amino acids); idebenone is mitochondrial energy + antioxidant. The cerebrolysin cycle is the structural-protection layer; idebenone is the daily metabolic-protection layer. Particularly well-paired for Dylan's MMA subconcussive-impact thesis — cerebrolysin supports neuroplasticity and recovery from impact insult, idebenone supports the underlying mitochondrial/membrane integrity that determines how badly an impact damages a neuron in the first place.
• mots-c / nad-plus precursors (NMN/NR): Both are mitochondrial-axis interventions. MOTS-c upregulates mitochondrial biogenesis at the genome/transcript level; NAD+ precursors restore the cofactor pool that drives sirtuins, NQO1, and ETC complex I; idebenone provides direct ETC bypass + membrane antioxidant. All three layer cleanly — different time-scales and mechanism levels, no competition, no documented interactions. NAD+ adequacy specifically helps idebenone's NQO1-dependent activation step.
• omega-3 / DHA (Dylan's V4 Carlson DHA Gems): Provides the lipid vehicle for absorption and the membrane substrate that idebenone protects from peroxidation. Take at the same meal.
• Curcumin (Dylan's V4 phytosome): Both Nrf2 activators; layered antioxidant gene induction; both fat-soluble; co-administration at breakfast is standard.
• Phosphatidylserine (Dylan's V4, 200 mg): Membrane phospholipid pool; idebenone protects membrane phospholipids from peroxidation; complementary at the membrane level.
• Apigenin / Magnesium L-threonate (Dylan's V4): No direct interaction; safe co-administration; both are layered cognitive maintenance tools.

Avoid stacking with

• High-dose CYP3A4 substrates with narrow therapeutic index at high idebenone doses (>600 mg/day): theoretical mild CYP3A4 inhibition (clinically minimal at therapeutic doses per the EMA label, but flag for cyclosporine, tacrolimus, certain statins, some antiarrhythmics). Not relevant for Dylan's stack.
• Isolated very-high-dose iron supplementation: theoretical pro-oxidant interaction (iron + quinones can drive Fenton chemistry); not clinically observed but worth noting if anyone stacks aggressive iron with high-dose idebenone.
• Aggressive ethanol use at high idebenone doses: hepatic load stacking. Not Dylan's situation (zero alcohol baseline).

Neutral / safe co-administration

• All V4 stack items: NAC, citicoline, magnesium, phosphatidylserine, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, creatine.
• All V5 cognitive additions: modafinil, bromantane, Adamax/Semax, taurine, apigenin.
• BPC-157 / TB-500 healing peptides — different mechanism, no interaction documented.

• CYP3A4: Mild in vitro inhibitor; clinically minimal at therapeutic doses (per the EMA Raxone label, midazolam exposure was not modified by 300 mg TID idebenone in 32 healthy volunteers). Flag for narrow-therapeutic-index CYP3A4 substrates only at supraclinical doses.
• CYP2D6 / CYP1A2 / CYP2C9 / CYP2C19: All metabolize idebenone (oxidative shortening of the side chain to QS10/QS8/QS6/QS4 metabolites). Inhibitors of CYP2D6 (fluoxetine, paroxetine, bupropion) or CYP3A4 (azole antifungals, grapefruit juice, ritonavir) could increase idebenone exposure. Pragmatically: if Dylan stacks bupropion (a CYP2D6 inhibitor) per his V5 contingency, idebenone exposure may rise — start at the low end of the dose range.
• Hepatotoxic co-medications: additive hepatic load — flag if Dylan ever uses high-dose acetaminophen, isotretinoin, methotrexate, or alcohol at idebenone doses >300 mg/day.
• Anticoagulants / antiplatelets: No documented interaction; theoretical mild antioxidant-pathway interaction, not clinically meaningful at supplement doses.
• Hormonal contraceptives: No documented interaction (CYP3A4 induction is not idebenone's mechanism).
• Statins: No documented interaction. Theoretical CYP3A4 angle has not produced clinical issues.

This is the single most important pharmacogenomic question for idebenone, and Dylan's June 2026 23andMe results may inform it directly.

• NQO1 (rs1800566 / C609T, a.k.a. P187S). NQO1 is the cytoplasmic enzyme that reduces idebenone to its active hydroquinone form. The C609T variant is a loss-of-function polymorphism: T/T homozygotes have nearly absent NQO1 activity; C/T heterozygotes have ~50% activity; C/C wild-type have full activity.
  • Population frequency: roughly 16-22% T allele frequency in Caucasians, similar or higher in Asian populations. ~25-50% of Caucasians carry at least one T allele.
  • Implication for idebenone response: NQO1 low-activity carriers may be poor responders. This hasn't been formally tested in a controlled trial in healthy adults, but it is the most parsimonious explanation for the responder/non-responder split observed in the LHON and DMD trials and in nootropic-community anecdotes.
  • Action: When Dylan's 23andMe lands (~June 2026), pull the NQO1 rs1800566 status. If C/C wild-type: idebenone trial is more likely to read out positive. If C/T or T/T: likely poor responder; consider deprioritizing or stacking with NAD+ precursors to maximize what NQO1 activity remains. (Note: 23andMe v5 chip coverage of rs1800566 is variable — may need to derive from imputation or order a follow-up panel.)
• CYP2D6 phenotype. Poor metabolizers (~7-10% of Caucasians) may have higher idebenone exposure → potentially better effect at lower doses, but also potentially earlier hepatic-enzyme signals. 23andMe will give CYP2D6 *2/*4/*5/*10/*17 calls — useful for general dose calibration.
• CYP3A4 / CYP3A5 variants. Less impactful than NQO1 for response; relevant only for high-dose interaction prediction.
• APOE4 carriers. Speculative — mitochondrial-membrane-stabilizing antioxidants that cross the BBB are theoretically more useful in APOE4-driven oxidative stress. No controlled stratified data. Worth flagging if Dylan's 23andMe returns APOE4: rationale strengthens, dose unchanged.

Bottom line: Idebenone is one of the few compounds in Dylan's pipeline where 23andMe results meaningfully change the prior probability of response. If you are going to spend $30-150/mo on this, wait for the NQO1 readout before locking in long-term use.

For Dylan's recommendation: RUPharma Noben 30 mg × 30 caps, 3 caps/day = 90 mg/day initial dose, ~$30-60/mo, runs through the same vendor pipeline he's already using for V5 Russian peptides. Step up to 180 mg/day (6 caps) if 30-day no-response and ALT/AST clean. Alternative: Antiaging Systems Idebex 45 mg if RUPharma channel adds friction.

Important sourcing flag: "Idebenone" on Amazon is overwhelmingly topical skincare (Prevage-style products by True Cosmetics et al.), not oral supplement. Do not assume the encyclopedia entry "$30-60/mo gray-market" maps to an Amazon-style click-through — it doesn't. The Russian gray-market or UK longevity-supplement rail is the actual path.

• Baseline (before starting):

  • ALT, AST, GGT — hepatic enzymes; the single most important watch panel.
  • Lipid panel (TC, LDL, HDL, TG) — for general antioxidant-effect tracking.
  • hsCRP — inflammation marker; changed in the 2024 aMCI trial.
  • Optional: SOD activity, MDA (oxidative-stress proxies, often only via specialty panels — relevant to the 2024 aMCI trial endpoints).
  • NQO1 rs1800566 genotype — single most informative pharmacogenomic call. Get from 23andMe v5 (verify chip coverage) or via a follow-up genomic panel.
  • CYP2D6 phenotype — from 23andMe.
  • Subjective: cognitive-fatigue rating at end of 6-12 hr workday (1-10); cognitive-clarity rating at hour 4 of focused work.

• During use (first 12 weeks, then every 6 months):

  • ALT/AST at week 8 at any dose >300 mg/day; at week 12 at 90-270 mg/day for first cycle baseline.
  • hsCRP, MDA, SOD at week 12 if specialty panel available.
  • Subjective cognitive clarity rating (looking for delta from baseline at weeks 4, 8, 12).
  • MoCA/MMSE at week 12 if Dylan wants formal cognitive tracking (overkill for healthy 20-year-old; useful for 50+ population).

• Post-cycle (if cycled): ALT/AST 4 weeks post-discontinuation if any prior elevation; otherwise none.

For Dylan specifically: tie this into the June 2026 baseline panel he already has scheduled. Add ALT/AST + GGT to the panel (already standard liver panel — should be there). NQO1 genotype derives from 23andMe; flag for follow-up panel if 23andMe coverage is thin on rs1800566.